{"id":"NCT01007591","sponsor":"LEO Pharma","briefTitle":"A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas","officialTitle":"Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-06","completion":"2010-12","firstPosted":"2009-11-04","resultsPosted":"2019-01-15","lastUpdate":"2025-03-07"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis Vulgaris"],"interventions":[{"type":"DRUG","name":"LEO 80190","otherNames":[]},{"type":"DRUG","name":"Hydrocortisone","otherNames":[]}],"arms":[{"label":"LEO 80190 ointment","type":"ACTIVE_COMPARATOR"},{"label":"Hydrocortisone 10 mg/g ointment","type":"ACTIVE_COMPARATOR"}],"summary":"An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and on the intertriginous areas","primaryOutcome":{"measure":"The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment","timeFrame":"From baseline (Day 0) to end of treatment (Week 8)","effectByArm":[{"arm":"LEO 80190 Ointment","deltaMin":-60.8,"sd":51.1},{"arm":"Hydrocortisone 10 mg/g Ointment","deltaMin":-54.2,"sd":59.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.75"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Nasopharyngitis","Pharyngolaryngeal pain","Headache","Influenza","Psoriasis"]}}